CNTB connectbiopharm.com: Forward P/S Multiple
Constant R&D expenditures in the absence of commercial products create a financial deficit, making the estimated forward P/S a key tool for analyzing expectations. The value of 14.10 serves as a baseline indicator for market valuation. Stable demand for asthma treatment offsets macroeconomic influence, while the retention of leading immunologists through stock options ensures that Connect Biopharma (CNTB) maintains its scientific potential.
connectbiopharm.com - analytical breakdowns and key metrics (CNTB)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
Debt to Equity Connect Biopharma|CNTB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Connect Biopharma Holdings Limited|CNTB - Company Cumulative Debt|Debts to Book Capitalization CNTB|CNTB - Company Long-Term Liabilities|Company Current Liabilities Connect Biopharma|Quick Liquidity Indicator connectbiopharm.com
- business earnings and investment ratios data:
CNTB - Final Profit|Projected Future Earnings Connect Biopharma|CNTB - Price to Earnings Ratio|Forward P/E Multiple Connect Biopharma Holdings Limited|CNTB - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CNTB|CNTB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Connect Biopharma|CNTB - Earnings per one share for the last 12 months|Quarterly EPS earnings growth connectbiopharm.com|CNTB - Earnings per share increase in current year|Earnings growth forecast for next year Connect Biopharma
- revenue and sales details:
Initial company analysis:Connect Pharma CNTB
Connect Biopharma revenues depend on the successful market launch of innovative therapies for autoimmune inflammation and atopic dermatitis. By analyzing the company's forward P/S chart, an investor assesses current capitalization relative to projected revenue, which allows them to filter out market noise and determine whether the market has already priced in the future commercialization of drugs or if the asset has become overvalued.
Competitors of Connect Biopharma (CNTB)
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Market Cap to Projected Revenue GRFS (Grifols SA)|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Celldex Corp - Market Cap to Projected Revenue|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Market Cap to Future Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|Dianthus Therapeutics Inc (DNTH) - Forward Price-to-Revenue Multiple|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|ABCL: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple TRML|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|Price-to-Projected Revenue Ratio NKTR (Nektar Therapeutics Inc)|Forward P/S Multiple UPB (Upstream Bio Corp)|Market Cap to Expected Sales Ratio Zenas Corp (ZBIO)|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio gossamerbio.com|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Future Price to Revenue SEPN (Septerna, Inc.)|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Price-to-Projected Revenue Ratio Astria Therapeutics, Inc. ATXS|Forward Price to Sales ENGN|RAPT - Price-to-Projected Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - Forward Price-to-Revenue Multiple|ACRS: Forward P/S Multiple|kyvernatx.com (KYTX) - Forward P/S Multiple|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Theratechnologies, Inc - Market Cap to Projected Revenue|Avalo Therapeutics, Inc - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ELDN (eledon.com)|Agenus Inc. - Forward P/S Multiple|CLYM: Price-to-Projected Revenue Ratio|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Future Price to Revenue ATYR (aTyr Pharmaceuticals)|ADAG (Adagene Inc) - Forward P/S Multiple|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Forward P/S Multiple equilliumbio.com (EQ)|Price-to-Projected Revenue Ratio Immunic IMUX|Forward Price to Sales ATRA|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|ACET: Forward P/S Multiple|Celularity (CELU) - Forward P/S Multiple|Forward Price-to-Revenue Multiple INMB|BRNS: Forward Price to Sales|Forward P/S Multiple KZR|Market Cap to Expected Sales Ratio sabbiotherapeutics.com|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|ENLV - Forward Price-to-Revenue Multiple|QTTB - Price-to-Projected Revenue Ratio|GeoVax Corp (GOVX) - Forward Price-to-Revenue Multiple|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|ibioinc.com (IBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Market Cap to Projected Revenue XTLB (XTL Biopharmaceuticals Ltd)|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM - Forward Price-to-Revenue Multiple|ADTX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio GRI Bio Inc|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HIND|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Forward P/S Multiple SCNI|CALI - Market Cap to Future Revenue Ratio|Forward P/S Multiple AFMD (Affimed N.V.)|ALLK - Forward Price-to-Revenue Multiple|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Inc - Forward Price to Sales|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Price-to-Projected Revenue Ratio THRD
